Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss among older people in the United States.1 Its treatment has been revolutionized...

By the year 2030, approximately half of all Americans will have diabetes. At the time of diagnosis, approximately 20% to 30% of people with diabetes will have some...

This activity provides a review of the properties and aesthetic uses of the currently available neuromodulators, or botulinum neurotoxin type A products, through a...

Patients undergoing ophthalmic surgery are prescribed topical medications to control postoperative inflammation and to prevent pain and other inflammation-related...

The prevalence of ocular disease is increasing as the population ages and as the incidence of metabolic disturbances such as diabetes increase. The number of patients...

Dry eye disease (DED) is increasing in prevalence because of an aging population and necessities of modern living (eg, office work and staring at computer screens and...

Neovascular age-related macular degeneration (nAMD) can be successfully treated with long-term monthly or bimonthly anti–vascular endothelial growth factor...

Dry eye disease is a common condition that is important to recognize and treat because of its potential to affect vision, ocular and contact lens wear comfort, ocular...

By 2030, approximately half of all Americans will have diabetes (55 million) or prediabetes (108 million), and approximately half of those will have some form of...

Glaucoma specialists, ophthalmologists, and optometrists all play a role in the management of glaucoma. Recently, the spectrum of glaucoma surgical procedures has...

This program will provide a case-based learning experience on cataract surgery, taking into account individual patient goals and comorbidities. Topics include...

Anti–vascular endothelial growth factor therapy is the clinical standard for first-line therapy of neovascular age-related macular degeneration. Although this therapy...